Mazdutide 10mg

Mazdutide (also known as IBI-362, LY-3305677, or OXM-3) is a synthetic peptide analog of oxyntomodulin, engineered with a fatty acid side chain to prolong its half-life and enable once-weekly administration in experimental models . This compound is characterized by its unique dual agonism, binding with high affinity to both the glucagon-like peptide-1 receptor (GLP-1R; Ki: 28.6 nM) and the glucagon receptor (GCGR; Ki: 17.7 nM) . Preclinical research indicates that this dual-action mechanism suppresses appetite and delays gastric emptying through GLP-1R activation, while simultaneously increasing energy expenditure and promoting hepatic lipid oxidation via GCGR signaling .

In laboratory investigations, Mazdutide has demonstrated significant improvements in metabolic parameters in diet-induced obesity and type 2 diabetes mouse models. Studies have shown that Mazdutide treatment reduces body weight, improves glycemic control, and alleviates hepatic fat accumulation to a greater extent than GLP-1R mono-agonists, an effect attributed to the upregulation of fatty acid oxidation pathways and the activation of transcription factors such as ATF3 . Emerging research also explores Mazdutide’s potential neuroprotective effects, with findings suggesting it may mitigate diabetes-associated cognitive dysfunction by modulating neuroinflammation and synaptic plasticity pathways in the hippocampus . This product is provided as a high-purity (≥99%) white to off-white lyophilized powder, suitable for reconstitution in sterile water or appropriate buffers. It is strictly for in vitro laboratory research use and is not approved for human therapeutic administration. Store lyophilized powder at -20°C or below, protected from light and moisture